Article of Significant Interest Selected from This Issue by the Editors

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-04-01 DOI:10.1128/CVI.00065-17

引用次数: 0

Abstract

Plasmodium vivax CelTOS Vaccine and Challenge There is no licensed vaccine against the most widely distributed human malaria parasite, Plasmodium vivax. The preerythrocytic stage is a highly attractive target for vaccination, but there is a need to assess novel vaccine candidates, platforms, and adjuvants to improve efficacy. Alves et al. (e00501-16) evaluated the protective efficacy of the Plasmodium vivax cell-traversal protein for ookinetes and sporozoites (PvCelTOS) using four different vaccine platforms and a transgenic parasite expressing the P. vivax CelTOS. Efficacy, albeit modest, was induced by an adenovirus-protein prime/boost regimen, and there was evidence of cross protection against the P. falciparum CelTOS.

查看原文本刊更多论文

由编辑从本期杂志中选出的具有重要意义的文章

间日疟原虫是一种分布最广泛的人类疟疾寄生虫，目前还没有获得许可的间日疟原虫疫苗。红细胞前阶段是一个非常有吸引力的疫苗接种目标，但有必要评估新的候选疫苗、平台和佐剂，以提高疗效。Alves等人(e00501-16)利用四种不同的疫苗平台和表达间日疟原虫CelTOS的转基因寄生虫，评估了间日疟原虫细胞穿越蛋白(PvCelTOS)的保护功效。虽然效果一般，但由腺病毒蛋白启动/增强方案诱导，并且有证据表明对恶性疟原虫有交叉保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.